**Supplementary Table 6: Net benefits for the CUA base case and sensitivity analyses – Analyses following multiple imputation**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Value of**  **threshold** | **Base case:**  **% cost-effective** | **Base case:**  **mean net benefit (95% CI)** | **Linear (U)**\*  **% cost-effective** | **Linear (U):**  **mean net benefit (95% CI)** | **Lower (U)**¶  **% cost-effective** | **Lower (U):**  **mean net benefit (95% CI)** | **Higher**  **(U)** #  **% cost-effective** | **Higher (U):**  **mean net benefit (95% CI)** | **Societal perspective:**  **% cost-effective** | **Societal perspective:**  **mean net benefit (95% CI)** |
| 0 | 53.7 | 6 (-165, 177) | 54.5 | 11 (-163, 197) | 52.5 | 2 (-173, 164) | 51.2 | 4 (-169, 172) | 51.3 | 1 (-185, 187) |
| 10,000 | 52.5 | 2 (-168, 173) | 31 | -45 (-223,138) | 51.3 | 0 (-174, 161) | 50.3 | 1 (-171, 169) | 49.9 | -3 (-186, 182) |
| 20,000 | 50.9 | -2 (-171,168) | 14.6 | -101 (-291, 89) | 50.6 | -1 (-175, 159) | 49.6 | -1 (-173, 166) | 48.4 | -6 (-188, 178) |
| 30,000 | 49.4 | -6 (-173, 162) | 8.3 | -158 (-367, 56) | 49.8 | -3 (-175, 156) | 48.7 | -4 (-175, 162) | 46.7 | -10 (-192, 172) |
| 40,000 | 48.2 | -9 (-175, 157) | 4.6 | -214 (-453,26) | 48.6 | -5 (-175, 154) | 47.8 | -6 (-178, 158) | 44.5 | -14 (-199, 166) |
| 50,000 | 46.8 | -13 (-177, 153) | 2.6 | -271 (-534, 4) | 47.8 | -7 (-175, 151) | 46.8 | -9 (-182, 155) | 43.1 | -18 (-204, 160) |
| 60,000 | 45.1 | -17 (-179, 151) | 1.7 | -327 (-621, -27) | 47.4 | -9 (-175, 148) | 45.4 | -11 (-184, 153) | 40.8 | -22 (-205, 154) |
| 70,000 | 43.3 | -21 (-182, 148) | 1.2 | -384 (-716, -51) | 46.3 | -11 (-175, 145) | 44.2 | -14 (-185, 151) | 39.1 | -25 (-207, 149) |
| 80,000 | 41.1 | -24 (-185, 144) | 1.0 | -440 (-798, -68) | 45.2 | -12 (-176, 144) | 43.1 | -16 (-188, 148) | 37.4 | -29 (-211, 146) |
| 90,000 | 38.7 | -28 (-188, 140) | 0.8 | -496 (-903, -90) | 44.7 | -14 (-177, 143) | 41.5 | -19 (-190, 146) | 36.0 | -33 (-213, 141) |
| 100,000 | 36.7 | -32 (-192,136) | 0.7 | -553 (-1006, -110) | 43.5 | -16 (-178, 142) | 41.0 | -21 (-194, 143) | 35.0 | -37 (-218, 138) |
| Multiple imputation based analysis included MgSO4 (n=252) and placebo (n=256).  \* Linear interpolation of health utilities over the entire follow-up period, rather than assuming that the health gain was achieved immediately following hospital discharge.  ¶ ‘Lower (U)’ denotes an assumption that baseline ASS scores mapped onto EQ-5D health states with lower utility scores than in the baseline analysis.  # ‘Higher U)’ denotes an assumption that baseline ASS scores mapped onto EQ-5D health states with higher utility scores than in the baseline analysis. | | | | | | | | | |  |